Single technology assessments of medicines
Published:
Changes
Medicines funded by the public have to be reasonably priced, taking into account its potential benefit and the severity of the disease. A novel medicine therefore undergoes a single technology assessment (STA).
The health technology developer prepares and provides documentation of the clinical benefit, safety and cost-effectiveness of a novel medicine. NOMA will then evaluate this documentation.